Ziylo’s biotech platform for treating diabetes was acquired for $800 million by Novo Nordisk. Dr Andy Chapman, Chief Scientific Officer of Ziylo, is an alumnus of the Ignite programme, run by the Entrepreneurship Centre at Cambridge Judge Business School.
Read the full article [Add URL domain here [ft.com]
Brain food 
Compass 
Entrepreneurship 
In the media 
Network 
News 
Reasons why 
The lowdown 
Thinkers
Comments